Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $9.84
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 9, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Sep 24, 26 | BTIG | maintain | Buy | Buy |
| Sep 24, 26 | Citigroup | upgrade | Neutral | Buy |
| Mar 18, 26 | B. Riley Securities | upgrade | Neutral | Buy |
| Mar 5, 26 | Citigroup | maintain | Buy | Buy |
| Mar 4, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Mar 4, 26 | Citigroup | maintain | Neutral | Neutral |
| Jan 6, 26 | Citigroup | maintain | Neutral | Neutral |
| Nov 13, 25 | Citigroup | maintain | Neutral | Neutral |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 35.03 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 9.37 | Oscillator | Buy |
| Williams %R (14) | -98.30 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.87 (Hist -0.27) | Oscillator | Strong Sell |
| Average Directional Index (14) | 17.18 (+DI 18.7 / -DI 29.2) | Trend | Neutral |
| EMA 20 | 11.94 | MA | Strong Sell |
| SMA 20 | 12.28 | MA | Strong Sell |
| EMA 50 | 12.08 | MA | Strong Sell |
| SMA 50 | 13.40 | MA | Strong Sell |
| SMA 200 | 8.90 | MA | Strong Buy |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G/A | Oct 7, 2026 | 2026-10-07 07:17:18 | View |
| 8-K | Sep 23, 2026 | 2026-09-23 16:11:34 | View |
| 8-K | Aug 25, 2026 | 2026-08-25 06:00:33 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 16:19:27 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:06:01 | View |
| 8-K | Jul 2, 2026 | 2026-07-02 07:05:55 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:02:14 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:01:54 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:01:35 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:01:18 | View |
Proxy statement (DEF 14A) disclosures
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 5, 26 | Holmes Edward W | director | A-Award | 15,000 @ $7.30 | $109.5K |
| Jun 5, 26 | Farrell Peter C | director | A-Award | 15,000 @ $7.30 | $109.5K |
| Jun 5, 26 | Barlow James F | director | A-Award | 15,000 @ $7.30 | $109.5K |
| Jun 5, 26 | Markels John | director | A-Award | 15,000 @ $7.30 | $109.5K |
| Jun 5, 26 | Slaoui Moncef | director | A-Award | 15,000 @ $7.30 | $109.5K |
| Jun 5, 26 | Marquet Magda | director | A-Award | 15,000 @ $7.30 | $109.5K |
| Jun 5, 26 | Marantz Jing L. | director | A-Award | 15,000 @ $7.30 | $109.5K |
| May 1, 26 | Mulroy Dennis | officer: Chief Financial Officer | A-Award | 100,000 @ $8.63 | $863.0K |
Stock news · updated daily
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program.
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company's next-generation mRNA delivery platform, and additional liver pipeline programs. “The ARCT-810 Phase 2 interim results validate Arcturus' m.
Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-term catalyst and ARCT-032 for cystic fibrosis in phase 2. ARCT-810 has shown promising phase 2 interim data, normalizing glutamine and ammonia levels, and is designated Orphan Drug, Fast Track, and Rare Pediatric Disease by the FDA. The upcoming Sep. 23 presentation on ARCT-810 could be stock-moving, but small trial sizes mean results should be viewed as hypothesis-generating.
Arcturus Therapeutics Holdings Inc. (the âCompanyâ, âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus' mRNA liver therapeutics pl.
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -1.00 | -0.84 | Beat 15.7% | $2.96M |
| May 7, 2026 | -1.03 | -0.95 | Beat 7.4% | $2.06M |
| Mar 3, 2026 | -0.92 | -1.03 | Miss -12.0% | $7.20M |
| Nov 10, 2025 | -0.80 | -0.49 | Beat 38.7% | $17.15M |
| Aug 11, 2025 | -0.89 | -0.34 | Beat 61.9% | $28.30M |
| May 12, 2025 | -1.58 | -0.52 | Beat 67.1% | $29.38M |
TTM vs. 5-year historical average (annual ratios)
| Metric | ARCT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -3.0x | 1.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -2.9x | EPS est. -3.43 | In line |
| Price / Book | 1.6x | 2.3x | Discount |
| Price / Sales | 11.8x | 18.4x | Discount |
| EV / EBITDA | -1.4x | -4.0x | Discount |
| Return on equity | -46.5% | — | Weak |
| Gross margin | 83.2% | 99.1% | Below hist. |
| Debt / Equity | 0.13 | 0.20 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -0.60 | Distress |
Discounted cash flow model
